Literature DB >> 26998136

A case of myeloproliferative neoplasm with a normal complete blood cell count: A novel problem of the JAK2 era.

Xiu-Peng Ye1, Shen Bao1, Huan-Min Gao1, Ying Guo1, Yu-Ping Wei1.   

Abstract

The present study reported a case of a myeloproliferative neoplasm (MPN) in a patient with a normal complete blood cell count. Bone marrow biopsy showed bone marrow hyperplasia, an elevated megakaryocyte count, megakaryocytic dysplasia and pleomorphic changes, multiple megakaryocyte clusters and focal reticulin fiber hyperplasia. Furthermore, genetic analysis revealed that the patient was positive for the JAK2-V617F mutation, and negative for the JAK2 exon 12 and 13 mutations and the BCR-ABL (p210) fusion gene. The patient's condition was basically stable and at the time of writing, the patient remained in a stable condition with no specific symptoms of disease. The present study also analyzed the diagnostic and clinical features of MPNs, and a literature review was performed. MPN with a normal complete blood cell count is a rare disease, and attention should be focused on this entity in the clinic.

Entities:  

Keywords:  JAK2 gene; myeloproliferative neoplasms

Year:  2016        PMID: 26998136      PMCID: PMC4774523          DOI: 10.3892/ol.2016.4192

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

1.  [Current problems in the diagnosis of Philadelphia-negative myeloproliferative neoplasms in Japan].

Authors:  Shuichi Shirane; Marito Araki; Soji Morishita; Yoko Edahiro; Akimichi Ohsaka; Norio Komatsu
Journal:  Rinsho Ketsueki       Date:  2015-07

Review 2.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

3.  The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Nancy Labastida-Mercado; Samantha Galindo-Becerra; Javier Garcés-Eisele; Perla Colunga-Pedraza; Valeria Guzman-Olvera; Virginia Reyes-Nuñez; Guillermo J Ruiz-Delgado; Guillermo J Ruiz-Argüelles
Journal:  Hematol Oncol Stem Cell Ther       Date:  2015-01-21

4.  [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].

Authors:  Sonia Mahjoub; Héla Baccouche; Mariam Sahnoun; Houda Kaabi; Zeineb Manai; Hmida Slama; Neila Ben Romdhane
Journal:  Tunis Med       Date:  2015-07

Review 5.  Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.

Authors:  Jean-Jacques Kiladjian
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

8.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

Review 9.  [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].

Authors:  A H Schmitt-Graeff
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

10.  Myeloproliferative Neoplasms in Children.

Authors:  Inga Hofmann
Journal:  J Hematop       Date:  2015-08-02       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.